{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:49:32Z","timestamp":1789123772439,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br Dent J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:bold>Introduction<\/jats:bold> This study aimed to assess the efficacy and safety of remimazolam for dental intravenous conscious sedation. It focused on evaluating sedation success rate, management of pre-operative anxiety, sedation depth, psychomotor recovery and variations in vital parameters.<\/jats:p>\n          <jats:p>\n            <jats:bold>Materials and methods<\/jats:bold> This single-centre, prospective cohort study involved 101 patients undergoing dental procedures. Sedation was administered according to the European Medicines Agency guidelines, and outcomes were assessed by: sedation success rates; anxiety reduction, as measured by the Visual Analogue Scale for Anxiety (VAS-A); depth of sedation, as assessed by the Ramsay Sedation Scale; psychomotor recovery, as assessed by the Newman test; and physiologic stability, defined as meeting Post-Anaesthetic Discharge Scoring System criteria.<\/jats:p>\n          <jats:p>\n            <jats:bold>Results<\/jats:bold> Remimazolam achieved an 100% procedural success rate without rescue sedatives. Pre-operative anxiety (mean MDAS: 16.87 \u00b1 4.80; mean VAS-A: 7.07) was effectively managed, with 69% of patients reporting high or very high anxiolytic effects. Vital parameters remained stable, with variations consistently &lt;20% from baseline values. Psychomotor recovery was rapid, with a mean recovery time of 49 minutes, and most patients were discharged within 60-90 minutes. Most patients (65%) experienced anterograde amnesia, while 74% described their preferred experience during the procedure as \u2018sleep' and 26% as \u2018calmness'. Minimal adverse effects were reported, and patient satisfaction scores were high (mean VAS satisfaction: 9.73).<\/jats:p>\n          <jats:p>\n            <jats:bold>Conclusions<\/jats:bold> Remimazolam demonstrated excellent efficacy, safety and patient satisfaction in dental procedural sedation. Its rapid recovery profile, minimal cardiovascular and respiratory impact, and effective anxiolytic properties establish it as a reliable alternative to midazolam, particularly for moderate- to high-risk patients. These findings support the integration of remimazolam into outpatient dental care, with the potential for broader application in paediatric and disabled populations.<\/jats:p>","DOI":"10.1038\/s41415-025-8664-9","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T09:46:14Z","timestamp":1755251174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Remimazolam besylate in intravenous conscious sedation for dental treatment: a prospective cohort study"],"prefix":"10.1038","author":[{"given":"Giovanni Battista","family":"Grossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Menozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Maiorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Galeotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scribante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Papaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Losappio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"8664_CR7865","unstructured":"Mesut E, \u00dclk\u00fc \u015eermet E, Emine K, \u00d6zlem Peyman K. Effects of photobiomodulation with different application parameters on injection pain in children: a randomized clinical trial. J Clin Pediatr Dent 2023; 47: 54-62."},{"key":"8664_CR7867","unstructured":"Vitale M C, Gallo S, Pascadopoli M, Alcozer R, Ciuffreda C, Scribante A. Local anesthesia with SleeperOne S4 computerized device vs traditional syringe and perceived pain in pediatric patients: a randomized clinical trial. J Clin Pediatr Dent 2023; 47: 82-90."},{"key":"8664_CR7869","unstructured":"Zanette G, Manani G, Favero L et al. Conscious sedation with diazepam and midazolam for dental patient: priority to diazepam. Minerva Stomatol 2013; 62: 355-374."},{"key":"8664_CR7872","doi-asserted-by":"crossref","unstructured":"Wang L, Jing Q, Pei L et al. Efficacy of continuous intravenous remimazolam versus midazolam in the extraction of impacted wisdom teeth: protocol of a randomised controlled trial. BMJ Open 2023; DOI: 10.1136\/bmjopen-2022-067908.","DOI":"10.1136\/bmjopen-2022-067908"},{"key":"8664_CR7874","doi-asserted-by":"crossref","unstructured":"Yang R, Zhao R, Chaudry F et al. Modern sedative agents and techniques used in dentistry for patients with special needs: a review. J Taibah Univ Med Sci 2024; 19: 153-163.","DOI":"10.1016\/j.jtumed.2023.10.004"},{"key":"8664_CR7876","doi-asserted-by":"crossref","unstructured":"Gonzalez Castro L N, Mehta J H, Brayanov J B, Mullen G J. Quantification of respiratory depression during pre-operative administration of midazolam using a non-invasive respiratory volume monitor. PLos One 2017; DOI: 10.1371\/journal.pone.0172750.","DOI":"10.1371\/journal.pone.0172750"},{"key":"8664_CR7878","doi-asserted-by":"crossref","unstructured":"Wandel C, B\u00f6cker R, B\u00f6hrer H, Browne A, R\u00fcgheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994; 73: 658-661.","DOI":"10.1093\/bja\/73.5.658"},{"key":"8664_CR7880","unstructured":"European Medicines Agency. Byfavo (remimazolam). 2023. Available at https:\/\/www.ema.europa.eu\/en\/documents\/overview\/byfavo-epar-medicine-overview_en.pdf (accessed 17 March 2025)."},{"key":"8664_CR7884","doi-asserted-by":"crossref","unstructured":"Li X, Tian M, Deng Y, She T, Li K. Advantages of sedation with remimazolam compared to midazolam for the removal of impacted tooth in patients with dental anxiety. J Oral Maxillofac Surg 2023; 81: 536-545.","DOI":"10.1016\/j.joms.2023.02.001"},{"key":"8664_CR7886","doi-asserted-by":"crossref","unstructured":"Sneyd J. Remimazolam - current status, opportunities and challenges. Anesthesiol Perioper Sci 2023; 1: 25.","DOI":"10.1007\/s44254-023-00021-7"},{"key":"8664_CR7888","doi-asserted-by":"crossref","unstructured":"Lee A, Shirley M. Remimazolam: a review in procedural sedation. Drugs 2021; 81: 1193-1201.","DOI":"10.1007\/s40265-021-01544-8"},{"key":"8664_CR7890","doi-asserted-by":"crossref","unstructured":"Jin N, Xue Z. Benefits of remimazolam as an anesthetic sedative for older patients: a review. Heliyon 2024; DOI: 10.1016\/j.heliyon.2024.e25399.","DOI":"10.1016\/j.heliyon.2024.e25399"},{"key":"8664_CR7892","doi-asserted-by":"crossref","unstructured":"Oka S, Satomi H, Sekino R et al. Sedation outcomes for remimazolam, a new benzodiazepine. J Oral Sci 2021; 63: 209-211.","DOI":"10.2334\/josnusd.21-0051"},{"key":"8664_CR7895","doi-asserted-by":"crossref","unstructured":"Guo Z, Wang X, Wang L, Liu Y, Yang X. Can remimazolam be a new sedative option for outpatients undergoing ambulatory oral and maxillofacial surgery? J Oral Maxillofac Surg 2023; 81: 8-16.","DOI":"10.1016\/j.joms.2022.09.008"},{"key":"8664_CR7897","doi-asserted-by":"crossref","unstructured":"Sun Y, Li Q. Evaluation of the efficacy and safety of remimazolam in tooth extraction surgery: a randomized, single-blind, multi-center clinical trial. Technol Health Care 2024; 32: 3473-3484.","DOI":"10.3233\/THC-240237"},{"key":"8664_CR7899","doi-asserted-by":"crossref","unstructured":"Kim E-J, Kim C-H, Yoon J-Y, Byeon G-J, Kim H Y, Choi E-J. Comparison of postoperative nausea and vomiting between remimazolam and propofol in patients undergoing oral and maxillofacial surgery: a prospective randomized controlled trial. BMC Anesthesiol 2023; 23: 132.","DOI":"10.1186\/s12871-023-02091-3"},{"key":"8664_CR7901","doi-asserted-by":"crossref","unstructured":"Oue K, Oda A, Shimizu Y et al. Efficacy and safety of remimazolam besilate for sedation in outpatients undergoing impacted third molar extraction: a prospective exploratory study. BMC Oral Health 2023; 23: 774.","DOI":"10.1186\/s12903-023-03538-2"},{"key":"8664_CR7904","doi-asserted-by":"crossref","unstructured":"Swart R, Maes S S A, Cavanaugh D, Mason K P. Remimazolam pilot for office-based dental sedation: adverse events, awareness and outcomes. J Clin Med 2023; 12: 7308.","DOI":"10.3390\/jcm12237308"},{"key":"8664_CR7906","doi-asserted-by":"crossref","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth 2019; DOI: 10.4103\/sja.SJA_543_18.","DOI":"10.4103\/sja.SJA_543_18"},{"key":"8664_CR7910","unstructured":"Intercollegiate Advisory Committee for Sedation in Dentistry. Remimazolam for intravenous conscious sedation for dental procedures. 2023. Available at https:\/\/www.rcseng.ac.uk\/-\/media\/fds\/iacsd\/iacsd-remimazolam-statement-130623.pdf (accessed 17 March 2025)."},{"key":"8664_CR7913","unstructured":"Intercollegiate Advisory Committee for Sedation in Dentistry. Standards for conscious sedation in the provision of dental care. 2020. Available at https:\/\/www.saad.org.uk\/IACSD%202020.pdf (accessed 17 March 2025)."},{"key":"8664_CR7916","unstructured":"European Medicines Agency. Byfavo: EPAR - summary of product characteristics. 2023. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byfavo-epar-product-information_en.pdf (accessed 17 March 2025)."},{"key":"8664_CR7919","unstructured":"Facco E, Gumirato E, Humphris G et al. Modified dental anxiety scale: validation of the Italian version. Minerva Stomatol 2015; 64: 295-307."},{"key":"8664_CR7921","unstructured":"Facco E, Stellini E, Bacci C et al. Validation of visual analogue scale for anxiety (VAS-A) in preanesthesia evaluation. Minerva Anestesiol 2013; 79: 1389-1395."},{"key":"8664_CR7924","doi-asserted-by":"crossref","unstructured":"Ducoulombier V, Chiquet R, Graf S et al. Usefulness of a visual analog scale for measuring anxiety in hospitalized patients experiencing pain: a multicenter cross-sectional study. Pain Manag Nurs 2020; 21: 572-578.","DOI":"10.1016\/j.pmn.2020.03.004"},{"key":"8664_CR7926","doi-asserted-by":"crossref","unstructured":"Dawson R, von Fintel N, Nairn S. Sedation assessment using the Ramsay scale. Emerg Nurse 2010; 18: 18-20.","DOI":"10.7748\/en2010.06.18.3.18.c7825"},{"key":"8664_CR7928","doi-asserted-by":"crossref","unstructured":"Newman M G, Trieger N, Miller J C. Measuring recovery from anesthesia - a simple test. Anesth Analg 1969; 48: 136-140.","DOI":"10.1213\/00000539-196948010-00028"},{"key":"8664_CR7930","unstructured":"Palumbo P, Tellan G, Perotti B, Pacil\u00e8 M A, Vietri F, Illuminati G. Modified PADSS (Post Anaesthetic Discharge Scoring System) for monitoring outpatients discharge. Ann Ital Chir 2013; 84: 661-665."},{"key":"8664_CR7933","doi-asserted-by":"crossref","unstructured":"American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures. an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology 2017; 126: 376-393.","DOI":"10.1097\/ALN.0000000000001452"},{"key":"8664_CR7936","doi-asserted-by":"crossref","unstructured":"Cowell A, Hare K, Campbell C. Adult intravenous sedation in general dental practice: indication, effectiveness and patient experiences. Br Dent J 2024; DOI: 10.1038\/s41415-024-7562-x.","DOI":"10.1038\/s41415-024-7562-x"},{"key":"8664_CR7938","doi-asserted-by":"crossref","unstructured":"Teixeira M T, Goyal A. Remimazolam. Adv Anesth 2024; 42: 131-150.","DOI":"10.1016\/j.aan.2024.07.010"},{"key":"8664_CR7940","doi-asserted-by":"crossref","unstructured":"St\u00f6hr T, Colin P J, Ossig J et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth 2021; 127: 415-423.","DOI":"10.1016\/j.bja.2021.05.027"},{"key":"8664_CR7942","doi-asserted-by":"crossref","unstructured":"Lawler H, Walker P. Evaluation of maximum dose intravenous midazolam used in dental intravenous sedation: a West of Scotland regional audit. Br Dent J 2022; 233: 135-138.","DOI":"10.1038\/s41415-022-4456-7"},{"key":"8664_CR7945","doi-asserted-by":"crossref","unstructured":"Kim H-J, Kim H, Park H-S, Kim H J, Ro Y-J, Koh W U. Effective remimazolam loading dose for adequate sedation in regional anesthesia. Can J Anaesth 2024; 71: 818-825.","DOI":"10.1007\/s12630-024-02698-1"},{"key":"8664_CR7947","doi-asserted-by":"crossref","unstructured":"Hu Q, Liu X, Wen C, Li D, Lei X. Remimazolam: an updated review of a new sedative and anaesthetic. Drug Des Devel Ther 2022; 16: 3957-3974.","DOI":"10.2147\/DDDT.S384155"},{"key":"8664_CR7949","doi-asserted-by":"crossref","unstructured":"Chen X, Sang N, Song K et al. Psychomotor recovery following remimazolam-induced sedation and the effectiveness of flumazenil as an antidote. Clin Ther 2020; 42: 614-624.","DOI":"10.1016\/j.clinthera.2020.02.006"},{"key":"8664_CR7951","doi-asserted-by":"crossref","unstructured":"Ito T, Utsumi N, Baba Y, Matsumura T, Wakita R, Maeda S. Considerations for satisfactory sedation during dental implant surgery. J Pers Med 2023; 13: 461.","DOI":"10.3390\/jpm13030461"},{"key":"8664_CR7954","doi-asserted-by":"crossref","unstructured":"Zhu X, Wang H, Yuan S et al. Efficacy and safety of remimazolam in endoscopic sedation-a systematic review and meta-analysis. Front Med 2021; 8: 655042.","DOI":"10.3389\/fmed.2021.655042"},{"key":"8664_CR7956","doi-asserted-by":"crossref","unstructured":"Dahiya D S, Kumar G, Parsa S et al. Remimazolam for sedation in gastrointestinal endoscopy: a comprehensive review. World J Gastrointest Endosc 2024; 16: 385-395.","DOI":"10.4253\/wjge.v16.i7.385"}],"container-title":["British Dental Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8664-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8664-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8664-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T09:46:31Z","timestamp":1755251191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41415-025-8664-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":39,"alternative-id":["8664"],"URL":"https:\/\/doi.org\/10.1038\/s41415-025-8664-9","relation":{},"ISSN":["0007-0610","1476-5373"],"issn-type":[{"value":"0007-0610","type":"print"},{"value":"1476-5373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest. This study was approved by the local ethical committee (Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico, Milan, Territorial Ethics Committee Lombardy 3) (Trial ID 4996) and complied with the fundamental principles of the 1964 Helsinki Declaration for clinical research involving human subjects (amended by the 75th World Medical Association General Assembly held in Helsinki, Finland, from October 16-19, 2024). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}}]}}